246 related articles for article (PubMed ID: 24123068)
1. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
3. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
Mele G; Pinna S; Melpignano A; Quarta G
Clin Ther; 2010 May; 32(5):915-9. PubMed ID: 20685499
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
9. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
12. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
14. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
[TBL] [Abstract][Full Text] [Related]
15. An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.
Spicka I; Mateos MV; Redman K; Dimopoulos MA; Richardson PG
Immunotherapy; 2011 Sep; 3(9):1033-40. PubMed ID: 21913826
[TBL] [Abstract][Full Text] [Related]
16. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
Telek B; Méhes L; Batár P; Kiss A; Udvardy M
Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
[TBL] [Abstract][Full Text] [Related]
17. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
18. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
